Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
Crossref DOI link: https://doi.org/10.1007/s12020-016-1182-4
Published Online: 2016-11-28
Published Print: 2017-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fleseriu, Maria
,
Rusch, Elisha
Geer, Eliza B.
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
License valid from 2016-11-28